中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.026 seconds)

    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER
    1.
    发明申请
    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER 审中-公开
    用于治疗癌症的方法和相关组合物

    公开(公告)号：WO2009148623A2

    公开(公告)日：2009-12-10

    申请号：PCT/US2009/003438

    申请日：2009-06-05

    Applicant: STC.UNM ,  THOMPSON, Todd, A. ,  MACKENZIE, Debra ,  OPREA, Tudor, I. ,  SKLAR, Larry, A. ,  EDWARDS, Bruce, S. ,  HAYNES, Mark

    Inventor： THOMPSON, Todd, A. ,  MACKENZIE, Debra ,  OPREA, Tudor, I. ,  SKLAR, Larry, A. ,  EDWARDS, Bruce, S. ,  HAYNES, Mark

    IPC: A61K31/445 ,  A61P35/00 ,  A61K31/165

    CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

    Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

    Abstract translation: 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这种细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中细胞内的粒度增加，并将粘附的癌细胞转化为非粘附的癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

    CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN-MEDIATED DISORDERS
    4.
    发明申请
    CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN-MEDIATED DISORDERS 审中-公开
    用于治疗原发性疾病的色胺衍生抗原

    公开(公告)号：WO2005011658A2

    公开(公告)日：2005-02-10

    申请号：PCT/US2004/005872

    申请日：2004-02-27

    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION ,  THOMPSON, Todd A. ,  WILDING, George

    Inventor： THOMPSON, Todd A. ,  WILDING, George

    IPC: A61K31/00

    CPC classification number: C07D311/72 ,  A61K31/353

    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.

    Abstract translation: 通过本发明提供了通过施用苯并二氢吡喃衍生的抗雄激素化合物可治疗的雄激素介导的疾病的预防和/或缓解方法。 本发明进一步提供了含有色氨酸衍生的抗雄激素化合物的药物和营养组合物，其用于预防和/或减轻雄激素介导的病症，特别是前列腺癌。

    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER
    5.
    发明申请
    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER 审中-公开
    用于治疗癌症的方法和相关组合物

    公开(公告)号：WO2009148623A3

    公开(公告)日：2010-03-25

    申请号：PCT/US2009003438

    申请日：2009-06-05

    Applicant: STC UNM ,  THOMPSON TODD A ,  MACKENZIE DEBRA ,  OPREA TUDOR I ,  SKLAR LARRY A ,  EDWARDS BRUCE S ,  HAYNES MARK

    Inventor： THOMPSON TODD A ,  MACKENZIE DEBRA ,  OPREA TUDOR I ,  SKLAR LARRY A ,  EDWARDS BRUCE S ,  HAYNES MARK

    IPC: A61K31/445 ,  A61K31/165 ,  A61P35/00

    CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

    Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

    Abstract translation: 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这种细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中细胞内的粒度增加，并将粘附的癌细胞转化为非粘附的癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

Patent Agency Ranking